Precise localization of phosphaturic mesenchymal tumor causing tumor-induced osteomalacia: the value of dual-tracer imaging with ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT [0.03%]
双示踪剂18F-FDG和68Ga-DOTATATE PET/CT显像对肿瘤诱发性骨软化相关磷调节性间质瘤精确定位的临床价值研究
Ting Ye,Xin Wen,Ruimin Wang
Ting Ye
Phosphaturic mesenchymal tumor (PMT) is a rare cause of tumor-induced osteomalacia (TIO), often presenting with nonspecific symptoms and small tumor size, leading to diagnostic challenges. We report a case of a 25-year-old male with progres...
Temporal shifts in diagnostic testing for cardiac amyloidosis across U.S. health systems [0.03%]
美国医疗体系中心肌淀粉样变性诊断检测的变迁趋势
Issam Motairek,Bryan Abadie,Andrew Higgins et al.
Issam Motairek et al.
Purpose: To evaluate temporal trends in diagnostic testing for cardiac transthyretin amyloidosis (ATTR-CM) across U.S. health systems in the contemporary era. ...
Tatiana Lopez Sandoval,Sebastian Peláez Arroyave,Juan Carlos Ramirez Yepes et al.
Tatiana Lopez Sandoval et al.
Splenosis is defined as the heterotopic implantation of functional splenic tissue in extra-splenic compartments, usually secondary to traumatic or iatrogenic splenic rupture (1). Although it is most commonly found in the abdominal and pelvi...
Patient and representative experience after amyloid PET/CT in a real-world memory clinic: a mixed-methods observational study [0.03%]
真实世界记忆诊所淀粉样PET/CT的患者和代表体验：一项混合方法观察性研究
Giulia Richina,Nathalie Testart Dardel,Paolo Salvioni et al.
Giulia Richina et al.
Background: Amyloid PET/CT is increasingly used in the diagnostic evaluation of cognitive disorders; however, its real-world impact on patient and caregiver experiences remains insufficiently characterised. This study exa...
Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223 [0.03%]
定量骨SPECT/CT衍生的肿瘤负荷作为Ra-223治疗转移性去势抵抗性前列腺癌的预后生物标志物
Yoshimitsu Fukushima,Go Kimura,Jun Akatsuka et al.
Yoshimitsu Fukushima et al.
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) is bone-predominant, requiring objective imaging biomarkers to guide Ra-223 therapy. We evaluated overall metabolic bone volume (OMBV) and overall total bon...
Ozgul Ekmekcioglu,Filiz Celik,Simon Hughes et al.
Ozgul Ekmekcioglu et al.
Fibroblast activation protein (FAP)-targeted PET imaging is an emerging technique that images the tumor stroma by targeting cancer-associated fibroblasts, offering high tumor-to-background contrast and improved lesion detection in tumors wi...
PET/CT contouring techniques in neuroendocrine neoplasms: a state-of-the-art scoping review [0.03%]
神经内分泌肿瘤的PET/CT勾画技术：一项最新的系统综述研究
Jacky Wt Chen,Paul J Roach,Nick Pavlakis et al.
Jacky Wt Chen et al.
Background: Neuroendocrine neoplasms (NENs) are often metastatic at diagnosis and show great variation in primary site and biological behaviour. Although PET is often used to image NENs, contouring is challenging because ...
An intrathyroidal cystic parathyroid adenoma localised with [18F]fluorocholine PET/CT in pregnancy [0.03%]
妊娠期甲状腺内甲状旁腺腺瘤的[18F]氟脱氧葡萄糖正电子发射体层显像/计算机断层成像定位一例
Sameer K Dave,Claire Mok,Stan Sidhu et al.
Sameer K Dave et al.
Primary hyperparathyroidism during pregnancy is rare but associated with substantial maternal and foetal morbidity, necessitating timely diagnosis and intervention. Intrathyroidal parathyroid adenomas account for as few as 0.7% of parathyro...
Breast cancer metastasis to the colon mimicking primary colorectal carcinoma [0.03%]
乳腺癌转移至结肠并模拟原发性结直肠癌
Qingkui Liu,Jianheng Gao,Hongxing Yang et al.
Qingkui Liu et al.
Breast cancer metastasis to the colon is rare, occurring in less than 1% of patients with metastatic breast cancer. Invasive lobular carcinoma (ILC) exhibits a distinct tropism for the gastrointestinal tract and adnexa, often presenting wit...
177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil [0.03%]
镥-PSMA-I&T治疗转移性去势抵抗性前列腺癌（mCRPC）：巴西首个镥-PSMA-I&T多中心真实世界研究
Helena F Bruzzi,Gabriela C K Lopes,Hannah B V Bekierman et al.
Helena F Bruzzi et al.
Purpose: Despite the approval of 177Lu-PSMA-617 as standard treatment for patients with mCRPC, at least 50% of patients do not respond to the therapy, especially those with visceral disease. This study analyzes real-world...